RMED Share Price | Catheter Precision, Inc. Stock Analysis & Recommendation

Q: How big is Catheter Precision, Inc.?

Market Cap: As of Jun 18, Catheter Precision, Inc. has a market capitalization of 4.19 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Catheter Precision, Inc. reported net sales of 0.48 million and a net profit of -18.01 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 11.76 million and total assets of 27.77 million.

Q: What does Catheter Precision, Inc. do?

Overview: Catheter Precision, Inc. is a medical device company focused on commercializing excimer lasers for the treatment of dermatological and vascular diseases, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot: Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) Most recent Net Profit: -4 Million (Quarterly Results - Mar 2025) Market-cap: USD 4.19 Million (Micro Cap)Key Metrics: Debt Equity: 1.47 Return on Equity: -184.16% Price to Book: 0.53Contact Details: Address: 2070 Las Palmas Dr, Carlsbad CA: 92011-1518 Tel: 1 760 8041648 Website: https://www.ramed.com/

Q: Is Catheter Precision, Inc. overvalued or undervalued?

As of 15 August 2022, the valuation grade for Catheter Precision, Inc. moved from risky to does not qualify, indicating a significant deterioration in its financial health. The company is currently deemed overvalued, primarily due to its negative earnings and poor performance metrics. The Price to Book Value stands at 0.29, while the EV to EBITDA is at -1.40, and the ROCE is a concerning -61.81%. In comparison to its peers, Catheter Precision's valuation ratios are notably worse; for instance, Cardio Diagnostics Holdings, Inc. has an EV to EBITDA of 0.5065, while Vivos Therapeutics, Inc. shows an EV to EBITDA of -1.0143. The stark contrast in these ratios highlights Catheter Precision's relative weakness in the market. Additionally, the company's stock has underperformed significantly, with a one-year return of -95.54% compared to a 10.26% return for the S&P 500, further reinforcing the notion that it is overvalued at its current price of $0.27.

Q: Is Catheter Precision, Inc. technically bullish or bearish?

As of 2 September 2025, the technical trend for Catheter Precision, Inc. has changed from bullish to mildly bullish. The weekly MACD is mildly bullish, while the monthly MACD is also mildly bullish. The monthly RSI indicates a bullish stance, but the weekly RSI shows no signal. However, the daily moving averages are bearish, and both the weekly and monthly KST and Dow Theory are bearish. The Bollinger Bands reflect a mildly bearish stance on both weekly and monthly time frames. In terms of performance, the stock has significantly underperformed compared to the S&P 500, with a year-to-date return of -68.61% versus the S&P 500's 12.22%, and a one-year return of -68.4% compared to 17.14% for the index. Overall, the current technical stance is mildly bullish but with considerable bearish indicators present, suggesting caution.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

11.22 k

Shareholding (Sep 2025)

FII

0.16%

Held by 5 FIIs

DII

99.63%

Held by 0 DIIs

Promoter

0.00%

How big is Catheter Precision, Inc.?

22-Jun-2025

As of Jun 18, Catheter Precision, Inc. has a market capitalization of 4.19 million, with net sales of 0.48 million and a net profit of -18.01 million over the latest four quarters. The company reported shareholder's funds of 11.76 million and total assets of 27.77 million as of Dec 24.

View full answer

What does Catheter Precision, Inc. do?

22-Jun-2025

Catheter Precision, Inc. is a micro-cap medical device company that develops excimer lasers for treating dermatological and vascular diseases. As of March 2025, it reported net sales of $0 million and a net loss of $4 million, with a market cap of $4.19 million.

View full answer

Is Catheter Precision, Inc. overvalued or undervalued?

25-Jun-2025

As of August 15, 2022, Catheter Precision, Inc. is considered overvalued with a valuation grade of "does not qualify" due to negative earnings, poor performance metrics, and a one-year stock return of -95.54%, significantly underperforming compared to its peers and the S&P 500.

View full answer

Is Catheter Precision, Inc. technically bullish or bearish?

20-Sep-2025

As of September 2, 2025, Catheter Precision, Inc. shows a mildly bullish trend overall, but significant bearish indicators and underperformance compared to the S&P 500 suggest caution.

View full answer

Compare Catheter Precision, Inc. with Similar Stocks

SINTX Technologies, Inc.Cardio Diagnostics Holdings, Inc.Heart Test Laboratories, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 3 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

1.87

Return on Equity

-207.98%

Price to Book

0.49

Revenue and Profits:

Net Sales:

0 Million

(Quarterly Results - Jun 2025)

Net Profit:

-5 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

65.79%

6 Months

-33.92%

1 Year

-76.67%

2 Years

-98.59%

3 Years

0.0%

4 Years

0.0%

5 Years

0.0%

Catheter Precision, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-35.96%

EBIT Growth (5y)

11.60%

EBIT to Interest (avg)

-22.51

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

1.47

Sales to Capital Employed (avg)

0.02

Tax Ratio

15.50%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

3.66%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.29

EV to EBIT

-1.16

EV to EBITDA

-1.40

EV to Capital Employed

0.71

EV to Sales

13.96

PEG Ratio

Dividend Yield

ROCE (Latest)

-61.81%

ROE (Latest)

-184.16%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 1 Schemes (0.2%)

Foreign Institutions

Held by 5 Foreign Institutions (0.16%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 100.00% vs 0.00% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -37.50% vs 28.57% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.20",
          "val2": "0.10",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.30",
          "val2": "-2.90",
          "chgp": "20.69%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-3.50",
          "val2": "-1.30",
          "chgp": "-169.23%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-5.50",
          "val2": "-4.00",
          "chgp": "-37.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-13,386.80%",
          "val2": "-24,167.80%",
          "chgp": "1,078.10%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 76.49% vs -162.45% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.40",
          "val2": "0.40",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-9.10",
          "val2": "-15.10",
          "chgp": "39.74%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-2.20",
          "val2": "-53.70",
          "chgp": "95.90%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-16.60",
          "val2": "-70.60",
          "chgp": "76.49%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-26,769.00%",
          "val2": "-38,880.10%",
          "chgp": "1,211.11%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

0.20

0.10

100.00%

Operating Profit (PBDIT) excl Other Income

-2.30

-2.90

20.69%

Interest

0.10

0.00

Exceptional Items

-3.50

-1.30

-169.23%

Consolidate Net Profit

-5.50

-4.00

-37.50%

Operating Profit Margin (Excl OI)

-13,386.80%

-24,167.80%

1,078.10%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is 100.00% vs 0.00% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -37.50% vs 28.57% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.40

Operating Profit (PBDIT) excl Other Income

-9.10

-15.10

39.74%

Interest

0.10

0.00

Exceptional Items

-2.20

-53.70

95.90%

Consolidate Net Profit

-16.60

-70.60

76.49%

Operating Profit Margin (Excl OI)

-26,769.00%

-38,880.10%

1,211.11%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 76.49% vs -162.45% in Dec 2023

All Annual Results

Company CV

About Catheter Precision, Inc.

Catheter Precision, Inc.

Pharmaceuticals & Biotechnology

Ra Medical Systems, Inc. is a medical device company. The Company is focused on commercializing excimer lasers for use in the treatment of dermatological and vascular diseases. It develops, manufactures and markets medical devices targeting the dermatology and vascular specialties. It operates through two segments: the vascular segment and the dermatology segment. The Company’s laser technology is used for the treatment of psoriasis, vitiligo, atopic dermatitis, leukoderma, and peripheral artery disease (PAD). Its Destruction of Arteriosclerotic Blockages by Laser Radiation Ablation (DABRA) is an excimer laser and disposable catheter system treatment of vascular blockages resulting from lower extremity vascular disease. Pharos is its excimer laser device that emits highly concentrated ultraviolet light and is used as a tool in the treatment of dermatological skin disorders.

Company Coordinates

Company Details

2070 Las Palmas Dr , Carlsbad CA : 92011-1518

Tel: 1 760 8041648

https://www.ramed.com/

Registrar Details

Catheter Precision, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Catheter Precision, Inc.?

Watch in Real-Time

What does Catheter Precision, Inc. do?

Is Catheter Precision, Inc. overvalued or undervalued?

Is Catheter Precision, Inc. technically bullish or bearish?

Compare Catheter Precision, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Annual Results Snapshot (Consolidated) - Dec'24

About Catheter Precision, Inc.

Company Coordinates